Both canonical and non-canonical isomiRs targeted well-known drivers of tumor progression, including master regulators of epithelial-mesenchymal transition (EMT), such as ZEB1 and ZEB2 (see ‘Discussion’ for details). The gene discussed is ZEB2; the disease is neoplasm.